Biogen Inc. (BIIB) Stock Analysis
By stockpickr AI | March 1, 2026 | 10 min read
Investment Summary
Biogen, a leader in biotechnology, appears to be slightly undervalued based on our DCF analysis, driven by potential pipeline advancements and market recovery in its key therapeutic areas.
Investment Recommendation
Buy
Fair Value: $235.00
Current Price: $210.35
Upside/Downside: +11.72%
Our DCF analysis suggests an implied fair value per share of approximately $235, indicating a slight upside from the current price of $210.35. This valuation is driven by assumptions of pipeline success and modest recovery in core business segments.
Key Metrics
- Market Cap: $37.3B
- P/E Ratio: 25.4x
- Forward P/E: 18.65x
- Revenue Growth (YoY): -0.44%
- Net Margin: 18.88%
- ROE: 11.29%
- Debt/Equity: 0.46
- Dividend Yield: 0%
Strengths
- Strong market position in multiple sclerosis with established drugs like Tysabri and Tecfidera.
- Significant investment in R&D with a diverse pipeline targeting challenging neurological diseases.
- Potential for growth with the Alzheimer's drug Lecanemab (Leqembi) gaining traction.
- Experienced management team with a proven track record in the biotechnology sector.
Risk Factors
- High R&D costs and the inherent failure rate of drug development.
- Stiff competition from other biotechnology and pharmaceutical companies.
- Regulatory hurdles and potential delays in drug approvals.
- Patent expirations and the subsequent loss of exclusivity for key products.